Restless Legs — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for restless legs. 28 active patents protecting 2 drugs from 2+ originators. First major cliff: 2026. Daily refresh.

2
Approved drugs
28
Active US patents
57/100
Avg vulnerability
—
Annual revenue covered

Originators in Restless Legs

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

UCB 24 patents Azurity 4 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating restless legs. Each bar = one year. Y-axis scaled to peak year (12 patents).

2
26
6
27
2
29
12
30
6
32

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Neupro
ROTIGOTINE
 UCB 24 56 — 2027-09-01
Horizant
GABAPENTIN ENACARBIL
 Azurity 4 57 — 2026-11-10

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
8246979 Neupro method of use 80 2027-09-01
8246979 Neupro method of use 80 2027-09-01
8246979 Neupro method of use 80 2027-09-01
8246979 Neupro method of use 80 2027-09-01
8246979 Neupro method of use 80 2027-09-01
8246979 Neupro method of use 80 2027-09-01
8795725 Horizant method of use 73 2029-06-10
8795725 Horizant method of use 73 2029-06-10
10350174 Neupro formulation 48 2030-12-22
10350174 Neupro formulation 48 2030-12-22

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
8026279 Horizant composition of matter 27 2026-11-10
8026279 Horizant composition of matter 27 2026-11-10
9925150 Neupro formulation 48 2032-03-01
9925150 Neupro formulation 48 2032-03-01
9925150 Neupro formulation 48 2032-03-01
9925150 Neupro formulation 48 2032-03-01
9925150 Neupro formulation 48 2032-03-01
9925150 Neupro formulation 48 2032-03-01
10350174 Neupro formulation 48 2030-12-22
10350174 Neupro formulation 48 2030-12-22

Related